KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2-Low, Hormone Receptor-Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials.

Stephen J Luen, Lauren C Brown, Courtney T van Geelen, Peter Savas, Roswitha Kammler, Patrizia Dell'Orto, Olivia Biasi, Alan S Coates, Richard D Gelber, Beat Thürlimann, Marco Colleoni, Gini F Fleming, Prudence A Francis, Meredith M Regan, Giuseppe Viale, Sherene Loi

JCO Precis Oncol 9 e2400599

PMID39854658
PMCIDPMC11835511
DOI10.1200/PO-24-00599
发表日期2025-01-24
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:已识别 KM 曲线,但未在图像中识别到 No. at risk 表,需人工复核正文或补充材料。
摘要

摘要

PURPOSE: To investigate whether hormone receptor-positive, human epidermal growth factor receptor 2-low (HR+HER2-low) versus HR+HER2-zero early breast cancers have distinct genomic and clinical characteristics. METHODS: This study included HR+, HER2-negative early breast cancers from patients enrolled in the phase III, randomized BIG 1-98 and SOFT clinical trials that had undergone tumor genomic sequencing. Tumors were classified HR+HER2-low if they had a centrally reviewed HER2 immunohistochemistry (IHC) score of 1+ or 2+ with negative in situ hybridization and HR+HER2-zero if they had an HER2 IHC score of 0. RESULTS: A total of 1,795 tumors were evaluable for this study (BIG 1-98 n = 520, SOFT n = 1,275). The frequency of HER2-low tumors was 37% and 21% in the postmenopausal BIG 1-98 and premenopausal SOFT cohorts, respectively. There were no significant differences in clinicopathologic variables between HER2-low and HER2-zero groups which was consistent across both trials. There was no significant difference in risk of distant recurrence for patients with HER2-low tumors versus HER2-zero tumors (5-year % distant recurrence-free 94.0% v 92.8%, P = .61, in BIG 1-98; 89.4% v 92.7%, P = .31, in SOFT, respectively). Somatic genomic profiles were similar with the exception of MAP3K1 mutations which were more frequent in HER2-zero tumors (BIG 1-98 19% v 5%, SOFT 11% v 6%). Both ERBB2 copy number and ERBB2 gene expression abundance were significantly higher in HER2-low tumors compared with HER2-zero tumors; however, the absolute difference was small. Correlation between ERBB2 copy number values and gene expression was modest (r = 0.17). CONCLUSION: In two large clinical trials with centrally reviewed HER2 IHC, our findings do not support HER2-low breast cancer as a distinct clinical or biologic entity among HR+HER2- early breast cancers. Absolute differences in median ERBB2 copy number levels or gene expression are small and of unclear biologic relevance.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Figure 3

Figure 3 A, Bar plot demonstrating the proportion of HER2-low tumours and HER2-zero tumours by age groups in BIG 1–98. B, Bar plot demonstrating the proportion of HER2-low tumours and HER2-zero tumours by age group in premenopausal SOFT cohort. C, Kaplan Meier estimate of distant recurrence-free interval by HER2-low status in postmenopausal BIG 1–98 cohort. D, Kaplan Meier estimate of distant recurrence-free interval by HER2-low status in SOFT premenopausal cohort. The hazard ratio characterises HER2-low relative to HER2-zero. Abbreviations: HR, hazard ratio; 95%CI, 95% confidence interval.

C

distant recurrence-free interval

Figure 3 · Panel C

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel C 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
D

distant recurrence-free interval

Figure 3 · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 A, Diagram demonstrating number of tumours that were evaluable for this analysis from the postmenopausal BIG 1–98 and premenopausal SOFT clinical trial genomic subsets. B, Bar chart displaying the proportion of evaluable tumours that were determined to be HER2-low in BIG1–98 and SOFT. C, Bar chart displaying the proportion of evaluable tumours with corresponding HER2 IHC score in BIG 1–98 and SOFT. HER2 IHC assessment was performed in the central lab. Abbreviations: IHC, immunohistochemistry.
非 KM Figure
Figure 2Figure 2 A, Box plots demonstrating centrally-assessed % tumour estrogen receptor IHC expression by HER2-low status. B, Box plots demonstrating centrally-assessed % tumour progesterone receptor IHC expression by HER2-low status. C, Bar plot demonstrating the proportion of tumours classified as centrally-assessed grade one, two, three, or unknown by HER2-low status. D, Box plots demonstrating centrally-assessed % Ki-67 IHC expression by HER2-low status.
非 KM Figure
Figure 4Figure 4 A, Plot demonstrating the frequency of genomic alteration in HER2-low versus HER2-zero tumours in postmenopausal BIG 1–98 trial cohort. B, Plot demonstrating the frequency of genomic alteration in HER2-low versus HER2-zero tumours in premenopausal SOFT trial cohort.
非 KM Figure
Figure 5Figure 5 A, Boxplot demonstrating the ERBB2 copy number LogR by HER2-low status according to trial cohort. The dotted horizontal line represents estimated LogR value for low level ERBB2 copy number gain (~4 copies) and the dashed horizontal line represents estimated LogR value for ERBB2 amplification (~6 copies). B, Boxplot demonstrating the ERBB2 transcript abundance by HER2-low status in postmenopausal BIG 1–98. C, Plot demonstrating the relationship between ERBB2 transcript abundance and ERBB2 copy number LogR in BIG 1–98.
非 KM Figure